Gain Therapeutics Inc. (NASDAQ: GANX)
$1.29
+0.0400 ( +3.20% ) 120.3K
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.
Market Data
Open
$1.29
Previous close
$1.25
Volume
120.3K
Market cap
$32.72M
Day range
$1.25 - $1.36
52 week range
$1.11 - $5.33
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 27 | Nov 22, 2023 |
8-k | 8K-related | 12 | Nov 17, 2023 |
10-q | Quarterly Reports | 88 | Nov 14, 2023 |
8-k | 8K-related | 15 | Nov 14, 2023 |
4 | Insider transactions | 1 | Oct 03, 2023 |
4 | Insider transactions | 1 | Sep 22, 2023 |
4 | Insider transactions | 1 | Sep 22, 2023 |
10-q | Quarterly Reports | 88 | Aug 10, 2023 |
8-k | 8K-related | 15 | Aug 10, 2023 |
4 | Insider transactions | 1 | Jul 05, 2023 |